- Home
- NUWE vs NCNA Comparison
NUWE vs NCNA Comparison
Compare NUWE & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NUWE | NCNA |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 7.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | NUWE | NCNA |
|---|---|---|
| Price | $2.17 | $3.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 47.6K | ★ 56.0K |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,167,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.48 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $2.78 |
| 52 Week High | $70.14 | $330.00 |
Technical Indicators
Market Signals| Indicator | NUWE | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 42.99 |
| Support Level | $2.10 | $3.30 |
| Resistance Level | $2.35 | $4.55 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 9.13 | 22.40 |
Price Performance
Historical ComparisonAbout NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.